Leadership

Executive Leadership

Prof. Mark Kendall

CEO & Founder

  • LinkedIn

(BE PhD FRSA FTSE): Mark is a world-leading expert and leader in R&D, project management and commercialisation of skin-based medical devices for global impact. While a Lecturer at Oxford University and Associate Director of the PowderJect Research Centre, Mark advanced biolistics technology, spun out to PowderJect (sold for $1.2 billion in 2003) and PowderMed (sold for $400 million in 2006). Then, in Australia as a Professor of Biomedical Engineering at The University of Queensland, he invented the Nanopatch and drove it forward – founding Vaxxas in 2011, securing $40 million of investment.  In 2018 Mark became an ANU Vice-Chancellor’s Entrepreneurial Professor and established WearOptimo.

Through his career Mark has built commercial healthtech enterprises with combined valuation of approximately $2 billion, an inventor on more than 140 medtech patents, secured seven major licensing deals for his patents including with big pharma and authored over 300 publications.  In recognition of his science, innovation and enterprise, Mark has received numerous awards and accolades including elected Fellow of The Australian Academy of Technology and Engineering (2017); in 2017 elected Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce) (2017); CSL Young Florey Medal (2016); elected into the World Economic Forum Global Future Council on Innovation Entrepreneurship (2016-2018); a 2015 World Economic Forum Technology Pioneer and a 2012 Rolex Laureate award for Enterprise.

Mark serves as the co-chair of the $150 million Australia Stem Cell Therapies Mission, reporting directly to Federal Health Minister Greg Hunt.  Mark is also serving on the World Economic Forum Global Future Council on Biotechnology and has been elected as a Fellow of the National Academy of Inventors (NAI).

Prof. Stephen Wilson

  • LinkedIn

Chief Technology Officer

(MBBS, M Biomed E, PhD): Steve has over 30 years of experience as a Medical Practitioner and  Biomedical Engineer. He has developed commercial MRI medical devices for most of his career. He has 15 patents, all of which have commercial interest and direct industrial applications. He was the Director of Biomedical Engineering at UQ. Steve has also worked as a medical officer in private practice and public hospital appointments.

Dr. Anthony Brewer

Head of R&D​

  • LinkedIn

(MPhys, PhD): Anthony has more than 10 years experience in leading roles in industry, start-ups, academia and medical device R&D in the UK, France and Australia. Anthony completed his PhD in physics from the University of Cambridge, led a team in Professor Kendall's spin out company (Vaxxas), and founded a start-up (agAlytics). He was awarded a Brisbane Lord Mayor’s Entrepreneur grant in 2016.

Renet DuPlessis

Chief Financial Officer

  • LinkedIn

Renet is a commercially focused senior finance executive, with over 25 years’ experience. She is a qualified chartered accountant, with a broad range of experience that includes start-up, privately held and multinational publicly traded companies. Previously, Renet was a Director with PwC and has experience in the Assurance and Private Client’s practice, specialising in external audit, technical accounting advice, business combinations and acquisition accounting, and preparation of financial statements. 

Rob Batchelor

Head of Commercial

  • LinkedIn

Rob is a scientific leader with more than 20 years of biotechnology industry experience ranging from startups to multinational biotech. He has developed and launched over 50 products into the life sciences market. Besides a Bachelor’s in Biochemistry and Masters in Pharmacology (both from the University of Washington, Seattle) Rob has deep experience in research and development, as well as product development, customer discovery, and commercialization.

Board of Directors

Prof. Mark Kendall

CEO & Founder

(BE PhD FRSA FTSE): Mark is a world-leading expert and leader in R&D, project management and commercialisation of skin-based medical devices for global impact. Through his career Mark has built commercial healthtech enterprises with combined valuation of approximately $2 billion, an inventor on more than 140 medtech patents, secured seven major licensing deals for his patents including with big pharma and authored over 300 publications. 

In recognition of his science, innovation and enterprise,

Mark has received numerous awards and accolades including elected Fellow of The Australian Academy of Technology and Engineering, Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce, and CSL Young Florey Medal to name a few.

Mark serves as the co-chair of the $150 million Australia Stem Cell Therapies Mission, reporting directly to Federal Health Minister Greg Hunt.  Mark is also serving on the World Economic Forum Global Future Council on Biotechnology and has been elected as a Fellow of the National Academy of Inventors (NAI).

Lusia Guthrie

Lusia Guthrie is a Company Director, founder, entrepreneur and experienced CEO. She has been involved in the health and biotech sectors for over 35 years in clinical pathology, pharmaceutical manufacturing, and medtech product development and commercialisation. She gives generously of her time and is actively engaged with industry, government and academia through various board, advisory and mentoring roles.

She currently serves as Non-Executive Director 4DMedical (ASX: 4DX); Chair Australian Lung Health Initiative Pty Ltd (ALHI); Chair BioMelbourne Network; and is a Member of the Innovation Taskforce for the State Government of Victoria.

Lusia is also a member of university industry advisory committees: Australian Institute for Machine Learning (AIML); Medicines Manufacturing Innovation Centre (MMIC); Australian Regenerative Medicine Institute (ARMI); and Swinburne Manufacturing Futures Research Institute.

Prof. Michael Cardew-Hall 

Professor Michael is Pro Vice-Chancellor (Innovation) at ANU, leading the ANU’s strategic initiatives to build growth in research and education outcomes through strategic partnerships with industry, government and not-for-profit organisations. ​

 

He is a Chartered Engineer and a Fellow of the Institution of Mechanical Engineers and Institution of Engineers Australia and has held technical and management positions with GEC and Rolls-Royce Aero Engines in the UK prior to joining ANU in 1993. ​He has served as a Director of the Australian Solar Institute, Lithicon AS, Simile Systems, ATPi and is currently Chair of the Boards of Australian Scientific Instruments and the Social Research Centre, and CEO of ANU Enterprise. 

Professor Michael Cardew-Hall was previously CEO of ANU Connect Ventures, a pre-seed venture capital fund associated with ANU and holds a seat on the ANU Connect Ventures Investment Committee. He also held the positions of Head of Department of Engineering, Deputy Dean, and Acting Dean of the College of Engineering and Computer Science at ANU.​

+61 7 3517 8000

2 Heaslop Street, Woolloongabba, QLD 4102, Australia

  • Twitter
  • LinkedIn

 

©2020 by WearOptimo